Personalis
Craig-Hallum Initiates Coverage of Personalis With Buy Rating
Craig-Hallum sees substantial growth opportunity in Personalis' pharma partnerships and focus on underpenetrated cancer markets.
Personalis Q4 Revenues Fall 15 Percent as Full-Year Revenues Jump on Molecular Test Sales
The company's full-year 2024 revenues jumped 15 percent as dwindling contract revenues were buoyed by an uptick in molecular testing sales.
The retrospective results suggest that the test's sensitivity boost over other platforms can overcome the challenge of detecting ctDNA in adenocarcinomas.
Personalis Preliminary Q4 Revenues Dip 15 Percent, Full-Year Revenues Rise 15 Percent
Declining revenues from Natera and the Million Veteran Program put pressure on quarterly revenues, while test and service sales buoyed full-year revenues.
Personalis Nabs $50M Investment From Merck, Extends Collaboration with Moderna
The company extended its collaboration to further advance an investigational personalized vaccine therapy under development by Merck and Moderna.
Jun 5, 2024
Dec 6, 2023